These findings suggest that AGR2 promotes the survival of pancreatic cancer cells and endows tumor cells with the protection from chemotherapeutic treatments, which possibly contributes to the fact that pancreatic cancer is widely recognized as highly resistant to therapeutic interventions. This evidence concerns the gene AGR2 and familial pancreatic carcinoma.